Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
01 August 2024 - 12:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August
2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
Exhibit
Number
|
Description
|
99.1
|
01
August 2024 - “Commencement of On-Market Share Buyback
Programme”
|
99.1
Haleon plc: Commencement of On-Market Share Buyback
Programme
1 August 2024: Haleon plc (the “Company”, or
“Haleon”) announces that, as set out in the 2024 Half
year results announcement released today, it is commencing a share
buyback programme to purchase ordinary shares of £0.01 each in
the Company (the “Shares”) up to an aggregate
consideration of £185 million (the “Buyback
Programme”), in line with its stated capital allocation
priorities.
The
Buyback Programme represents the remainder of the £500 million
allocated to share buybacks in 2024 announced on 29 February 2024,
following completion of the off-market purchase of Shares from
Pfizer Inc. announced on 21 March 2024. All Shares purchased by the
Company under the Buyback Programme will be cancelled. The purpose
of the Buyback Programme is to reduce share capital and is in line
with the Company’s capital allocation
priorities.
The
Company has entered into an arrangement with HSBC Bank plc
(“HSBC”) for the purchase by HSBC (acting as principal)
of the Shares through daily instructions that may be provided by
Haleon during the Buyback Programme. Under the Buyback
Programme, Haleon will, subject to applicable law and regulation,
have discretion as to whether to provide a daily instruction to
HSBC. No daily instructions will be provided by Haleon during its
closed periods.
The
Buyback Programme commences today and will end no later than 31
December 2024. Under the terms of the Buyback Programme, any
purchase of Shares by HSBC will be carried out on the London Stock
Exchange.
There
is no guarantee that the Buyback Programme will be implemented in
full or of the number of Shares that will be bought back by the
Company. The Company will make further regulatory announcements in
respect of purchases of Shares under the Buyback Programme as they
occur.
Notes
The
maximum number of Shares that may be purchased under the Buyback
Programme is 913,000,000, being the number of Shares the Company is
authorised to purchase pursuant to its general authority to make
market purchases granted at its Annual General Meeting held on 8
May 2024 (the “AGM Authority”). To date, no Shares have
been purchased pursuant to the AGM Authority.
Any
purchases of Shares contemplated by this announcement will be
effected within certain pre-set parameters. The Buyback Programme
will operate in accordance with (i) the AGM Authority; (ii) the
assimilated UK Market Abuse Regulation No. 596/2014 and assimilated
Commission Delegated Regulation (EU) 2016/1052 (in each case as
they form part of law of the United Kingdom by virtue of the
European Union (Withdrawal) Act 2018) and (iii) Chapter 9 of the UK
Financial Conduct Authority’s UK Listing Rules.
Enquiries
|
|
Investors
|
Media
|
Sonya
Ghobrial
|
+44
7392 784784
|
Zoë
Bird
|
+44
7736 746167
|
Rakesh
Patel
|
+44
7552 484646
|
Gemma
Thomas
|
+44
7985 175048
|
Emma
White
|
+44
7823 523562
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
About Haleon
Haleon
(LSE / NYSE: HLN) is a global leader in consumer health, with a
purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For
more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
HALEON PLC
(Registrant)
|
Date:
August 01, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
Name:
|
Amanda
Mellor
|
|
|
Title:
|
Company
Secretary
|
Haleon (PK) (USOTC:HLNCF)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Haleon (PK) (USOTC:HLNCF)
Historical Stock Chart
Von Sep 2023 bis Sep 2024